Life Sciences company focusing on research and development of therapeutics of infectious diseases and rare disorders Revive Therapeutics Ltd. (CSE: RVV) announced having entered into an agreement with University of Health Sciences Antigua (UHSA) to join efforts and work together on clinical research and development of psychedelics.
This research involves novel psychedelic assisted therapies by Revive Therapeutics and it will be taking place in Barbuda and Antigua.
Both parties aim to accomplish a number of activities in the proposed partnership among them establishment of a Master’s psychedelic medicine program for Doctor of Medicine students and those seeking to expand their knowledge in the psychedelic medicine field.
“Through our partnership with Revive Therapeutics, we have the unique opportunity to become a regional leader in the research of psychoactive therapies for mental health. Our medical students will now have access to the scientific knowledge and uses of treatments long before joining the physician workforce, which is a great benefit. We too are excited to partner with Revive as we contribute to the future of medicine,” said the president of UHSA, Dr. Adedayo Akande.
